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Abstract
Muc1 (MUC1 in humans) is a membrane-tethered mucin that exerts anti-inflammatory effects in
the lung during bacterial infection. Muc1 and other mucins are also likely to form a protective
barrier in the lung. We used mouse adenovirus type 1 (MAV-1, also known as MAdV-1) to
determine the role of Muc1 in the pathogenesis of an adenovirus in its natural host. Following
intranasal inoculation of wild type mice, we detected increased TNF-α, a cytokine linked to Muc1
production, but no consistent changes in the production of lung Muc1, Muc5ac or overall lung
mucus production. Viral loads were modestly higher in the lungs of Muc1−/− mice compared to
Muc1+/+ mice at several early time points but decreased to similar levels by 14 days post infection
in both groups. However, cellular inflammation and the expression of CXCL1, CCL5, and CCL2
did not significantly differ between Muc1−/− and Muc1+/+ mice. Our data therefore suggest that
Muc1 may contribute to a physical barrier that protects against MAV-1 respiratory infection.
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Many epithelial surfaces are covered by a layer of mucus that serves as a barrier between the
external environment and the host. The mucins are glycosylated proteins that are major
constituents of these mucus layers. The gel-forming mucins are secreted proteins that are
produced by the surface epithelium and submucosal glands and are released both
constitutively and in response to a variety of stimuli (Thornton et al., 2008). The membrane-
tethered (cell-surface) mucins are physically associated with epithelial cells via membrane-
spanning domains (Hattrup and Gendler, 2008). In the airways, mucus contributes to host
defense by trapping pathogens and other particles and facilitating their clearance from the
lungs by ciliary transport and cough (Knowles and Boucher, 2002). In some cases, mucins
may have functions beyond serving as a protective barrier. For instance, MUC1 (Muc1 in
nonhumans) is a membrane-tethered mucin that is expressed on a variety of cell types
including most secretory epithelial cells as well as some hematopoietic cells (Chang et al.,
2000; Gendler, 2001). In addition to serving as a cell-surface adhesion site for Pseudomonas
aeruginosa (Lillehoj et al., 2001), Muc1 has an anti-inflammatory role. Muc1 negatively
regulates signaling through a variety of Toll-like receptors (TLRs) in vitro (Ueno et al.,
2008), and knockdown of MUC1 in a lung epithelial cell line results in increased tumor
necrosis factor (TNF)-α production following respiratory syncytial virus (RSV) infection (Li
et al., 2010). In vivo, there is increased inflammation and enhanced pulmonary clearance of
P. aeruginosa from lungs of Muc1−/− mice (Lu et al., 2006).
Increased mucus production is a common feature of respiratory viral infections and is
thought to contribute to the symptoms of acute infection and to virus-induced asthma
exacerbations (Footitt and Johnston, 2009). Many viruses induce lung mucus production in
animal models, including respiratory syncytial virus (RSV) (Moore et al., 2009), human
metapneumovirus (Hamelin et al., 2006), and human rhinovirus (Bartlett et al., 2008). TNF-
α induced by RSV infection upregulates MUC1 production in a human lung epithelial cell
line (Li et al., 2010), but to our knowledge no other reports exist that describe the effects of
viral infection on MUC1/Muc1 production in vitro or in vivo.
Human adenoviruses (HAdVs) are common causes of respiratory infections that can present
with syndromes ranging from mild upper respiratory tract infections to more severe, life-
threatening manifestations (Horwitz, 2001). Immunocompromised patients are at risk for
greatly increased morbidity and mortality from HAdV infections (Kojaoghlanian et al.,
2003; Walls et al., 2003). Little is known about the role of mucus in HAdV pathogenesis.
An empty HAdV-based vector does not induce mucus production in mouse lungs (Therien et
al., 2008). HAdV-mediated gene transfer in mice engineered to express the human
coxsackievirus and adenovirus receptor (CAR) is more efficient in the lungs of Muc1-
deficient mice (Stonebraker et al., 2004), suggesting that Muc1 may serve as a barrier to
adenovirus infection. Exposure of mice to HAdV does not result in a fully permissive
infection (Ginsberg et al., 1991; Kajon et al., 2003). This species-specificity of the
adenoviruses has precluded a thorough analysis of interactions between lung mucins and an
adenovirus in the natural host of the virus.
We have established mouse adenovirus type 1 (MAV-1, also known as MAdV-1) as a useful
model to study the pathogenesis of adenovirus respiratory infection (Anderson et al., 2009;
Weinberg et al., 2007; Weinberg et al., 2005). In this report, we use MAV-1 to characterize
the role of Muc1 in the pathogenesis of adenovirus respiratory infection, taking advantage of
the ability to study the pathogenesis of an adenovirus in its natural host. We demonstrate
that acute MAV-1 respiratory infection does not substantially increase Muc1 expression in
the lungs of mice. MAV-1 viral loads were higher in the lungs of Muc1-deficient mice, but
Muc1 deficiency had minimal effect on MAV-1-induced pulmonary inflammation. Our data
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suggest that Muc1 may serve as a physical barrier to MAV-1 infection in the lungs.
However, the previously identified negative regulatory effect of Muc1 on inflammatory
signaling pathways does not appear to make substantial contributions to MAV-1
pathogenesis.
2. Materials and Methods
2.1. Virus
MAV-1 was grown in NIH 3T6 fibroblasts and titers were determined by plaque assay as
previously described (Cauthen et al., 2007).
2.2. Mice
Mice with targeted deletions of the Muc1 gene (Muc1−/− mice) backcrossed onto a C57BL/
6 background (Spicer et al., 1995) were obtained from Sandra Gendler (Mayo Clinic,
Scottsdale, AZ) and bred at the University of Michigan. Genotype was confirmed for all
Muc1−/− animals (data not shown). Wild type C57BL/6 mice (referred to hereafter as
Muc1+/+ mice) used as controls were obtained from The Jackson Laboratory (Bar Harbor,
ME). All animal work was conducted according to relevant national and international
guidelines. All animal work was approved by the University of Michigan Committee on the
Use and Care of Animals (approval #9054).
2.3. Mouse Infections
Mice were anesthetized and inoculated intranasally (i.n.) with 105 p.f.u. of MAV-1 diluted
to a total volume of 40 μl with sterile phosphate-buffered saline (PBS). In some
experiments, mock infected control animals were instead inoculated i.n. with an equivalent
volume of conditioned media diluted to a total volume of 40 μl with PBS. Before infection
and then again at multiple time points post infection, organs were harvested and snap-frozen
on dry ice and stored at −80°C.
2.4. DNA and RNA Isolation from Mouse Organs
DNA was extracted from the middle lobe of the right lung or approximately 30 mg of the
spleen using the DNeasy Tissue Kit (Qiagen, Valencia, CA). Total RNA was extracted from
lungs as previously described (Nguyen et al., 2008). In brief, approximately one-third of
each lung was homogenized using sterile glass beads in a mini Beadbeater (Biospec
Products, Bartlesville, OK) for 30 seconds in 1 ml of TRIzol. RNA was then isolated from
the homogenates according to the manufacturer's protocol.
2.5. Analysis of Viral Load and Viral Gene Expression in Mouse Organs
MAV-1 viral loads were measured in organs using quantitative real-time PCR (qPCR) as
previously described (Anderson et al., 2009; Nguyen et al., 2008). We use qPCR
measurements of MAV-1 viral loads and viral gene expression as sensitive and rapid ways
to assess viral replication in the lungs of infected mice. Peak levels of DNA viral loads and
viral gene expression occur at time points at which we have been able to detect infectious
virus in the lungs by plaque assay, and logarithmic decreases in DNA viral loads at later
time points correlate with the clearance of infectious virus from the lungs (Weinberg et al.,
2005 and unpublished data). Primers and probe (Table 1) were used to detect a 59-bp region
of the MAV-1 EIA gene. 5 μl of extracted DNA were added to reactions containing TaqMan
Universal PCR Mix (Applied Biosystems, Foster City, CA), forward and reverse primers
(each at 200 nM final concentration) and probe (200 nM final concentration) in a 25 μl
reaction volume. Analysis on an ABI Prism 7300 machine (Applied Biosystems, Foster
City, CA) consisted of 40 cycles of 15 seconds at 90°C and 60 seconds at 60°C. Standard
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curves generated using known amounts of plasmid containing the MAV-1 E1A gene were
used to convert cycle threshold values for experimental samples to copy numbers of E1A
DNA. Results were standardized to the ng amount of input DNA. Each sample was assayed
in triplicate.
Expression of the MAV-1 hexon gene was measured using reverse transcriptase qPCR (RT-
qPCR). 2.5 μg of RNA were reverse transcribed using MMLV reverse transcriptase
(Invitrogen, Carlsbad, CA) in 20 μl reactions according to the manufacturer's instructions.
Primers and probe (Table 1) were used to detect a 167-bp region of the MAV-1 hexon gene.
2 μl of cDNA were added to a reaction containing TaqMan Universal PCR Mix (Applied
Biosystems, Foster City, CA), forward and reverse primers (each at 200 nM final
concentration) and probe (200 nM final concentration) in a 25 μl reaction volume. Separate
reactions were prepared with 2 μl of cDNA, 1.25 μl of 20× mouse GAPDH gene expression
assay (Applied Biosystems, Foster City, CA) and TaqMan Universal PCR Mix in a 25 μl
reaction volume. In each case, RT-qPCR analysis consisted of 40 cycles of 15 seconds at
90°C and 60 seconds at 60°C. Standard curves generated using known amounts of plasmid
containing the MAV-1 hexon gene or the mouse GAPDH gene were used to convert cycle
threshold values for experimental samples to copy numbers of hexon and GAPDH
transcripts, respectively. Copy numbers of viral transcripts were normalized to copy
numbers of GAPDH transcripts for each sample. In a subset of samples prepared without
using reverse transcriptase, we verified that trace amounts of contaminating DNA in the
RNA samples contributed only a negligible amount to hexon copy numbers detected using
RT-qPCR.
2.6. Analysis of Cytokine and Mucus Gene Expression
Cytokine and mucus gene expression was quantified using RT-qPCR. cDNA prepared as
described above was amplified using gene expression assays for mouse CXCL1, CCL5,
CCL2, and GAPDH (Applied Biosystems, Foster City, CA). 2 μl of cDNA were added to
reactions containing TaqMan Universal PCR Mix and 1.25 μl each of 20× gene expression
assays for the target cytokine and GAPDH. Primers used to detect TNF-α, interferon (IFN)-
γ, Muc1, and Muc5ac are described in Table 1. For these measurements, 2 μl of cDNA were
added to reactions containing TaqMan Power SYBR Green PCR Mix (Applied Biosystems,
Foster City, CA) and forward and reverse primers (each at 200 nM final concentration) in a
25 μl reaction volume. Separate reactions were prepared with primers for mouse GAPDH
(Table 1, used at 167 nM each). RT-qPCR analysis consisted of 40 cycles of 15 seconds at
90°C and 60 seconds at 60°C. Quantification of target gene expression was normalized to
GAPDH and expressed as fold change from control groups using the comparative CT
method (Fink et al., 1998).
2.7. Protein Extraction from Lung Homogenate
Lung tissue was homogenized using sterile glass beads in a mini Beadbeater (Biospec
Products, Bartlesville, OK) for 3 cycles of 30 seconds each. Tissue was homogenized at 100
mg per 1 ml of CellLytic™ MT Cell Lysis Reagent (Sigma, St. Louis, MO) with protease
inhibitor (complete, Mini, EDTA-free tablets; Roche Applied Science, Indianapolis, IN).
Samples were centrifuged in a refrigerated microcentrifuge at 13,500 rpm (17,136 × g) for
10 min at 4°C to pellet debris, and the remaining supernatant was stored at −20°C.
2.8. Analysis of Cytokine Protein Production
Measurements of cytokine protein concentrations in lung homogenate were performed by
ELISA (Duoset Kits, R&D Systems, Minneapolis, MN) according to the manufacturer's
suggested protocol.
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2.9. Detection of Muc1 Protein
25 μg of lung homogenate protein per sample were separated on a 4–15% gradient
acrylamide gel and transferred to PVDF membrane (Bio-Rad Laboratories, Hercules, CA).
Membranes were blocked overnight with tris-buffered saline-Tween (TBST; 150 mM NaCl,
10 mM Tris, 0.1% Tween 20) containing 5% nonfat dry milk. The membrane was then
incubated overnight with a rabbit monoclonal anti-MUC1 antibody that cross-reacts with
mouse Muc1 (Clone EP1024Y, OriGene, Rockville, MD; 1:2000 in 5% nonfat dry milk/
TBST) or for 1 h with a rabbit polyclonal anti-β-actin antibody (sc-1616-R, Santa Cruz
Biotechnology, Santa Cruz, CA; 1:500 in 5% nonfat dry milk/TBST. Membranes were
incubated for 1 h with secondary antibody (horseradish peroxidase-conjugated goat anti-
rabbit IgG antibody, Pierce Biotechnology, Rockford, IL; 1:20,000 in 5% nonfat dry milk/
TBST). Protein bands were detected with a Chemi Doc XRS (Bio-Rad Laboratories,
Hercules, CA) and band densities were quantified using Quantity One software (Bio-Rad
Laboratories, Hercules, CA).
2.10. Histology Evaluation
Lungs were fixed in 10% formalin and embedded in paraffin, and then 5 μm sections were
cut for histopathology. Sections were stained with hematoxylin and eosin to evaluate cellular
infiltrates. PAS staining was performed to evaluate mucus production. Digital images were
obtained with an EC3 digital imaging system (Leica Microsystems) using Leica Acquisition
Suite software (Leica Microsystems, Inc., Bannockburn, IL). Final images were assembled
using Adobe Illustrator (Adobe Systems, San Jose, CA).
To quantify cellular inflammation in the lungs, slides were examined in a blinded fashion to
determine a pathology index as previously described (Anderson et al., 2009), generating
scores for the severity of cellular infiltrates around airway lumens and pneumonitis (Table
2). Each score was multiplied by a number reflecting the extent of involvement in the lung
(5% to 25% = 1, >25% to 50% = 2, >50% = 3). The final pathology index was obtained by
adding together the values for cellular infiltrates around airway lumens and for pneumonitis.
2.11. Statistics
Analysis of data for statistical significance was conducted using Prism 3 for Macintosh
(GraphPad Software, Inc., La Jolla, CA). For viral load and viral gene expression data,
differences between groups at a given time point were analyzed using the Mann-Whitney
rank sum test. For pathology scores, cytokine and mucus gene expression data, and cytokine
protein data, differences were analyzed using two-way ANOVA followed by Bonferroni's
multiple comparison tests to analyze differences between two groups at each time point. P
values less than 0.05 were considered statistically significant.
3. Results
3.1. Effects of Acute MAV-1 Infection on Lung TNF-α Expression
TNF-α induces the expression of MUC1 in lung epithelial cells (Koga et al., 2007), and
TNF-α inhibition suppresses MUC1 induction following in vitro RSV infection of
respiratory epithelial cells (Li et al., 2010). Because of these links between TNF-α and
Muc1, we sought to determine whether acute MAV-1 respiratory infection increased the
production of TNF-α in the lungs. As shown in Fig. 1A, we examined time points
corresponding to an early time at which viral DNA is detected in the lungs of infected mice
(4 d.p.i.), a time coinciding with peak lung viral loads (7 d.p.i.), and a later time
corresponding to clearance of the majority of viral DNA (14 d.p.i.). TNF-α mRNA levels
measured by RT-qPCR were slightly increased in the lungs of infected mice compared to
mock infected mice at 4 d.p.i. (Fig. 1B). This difference increased and reached statistical
Nguyen et al. Page 5













significance by 7 d.p.i. Lung TNF-α mRNA levels in infected animals decreased to pre-
infection levels by 14 d.p.i. We also used ELISA to measure TNF-α protein in lung
homogenates at select time points (Fig. 1C). While TNF-α protein concentrations did not
differ between mock infected and infected animals at 7 d.p.i., we detected a statistically
significant increase in TNF-α protein in the lungs of infected mice compared to mock
infected mice at 14 d.p.i.
3.2. Effects of Acute MAV-1 Infection on Lung Muc1 Expression
To assess the effects of MAV-1 respiratory infection on lung Muc1 production, we used RT-
qPCR to quantify Muc1 expression in the lungs of infected and mock infected mice.
Compared to pre-infection baseline levels, no increases in Muc1 mRNA were detected in
either mock infected or infected mice at 4 or 7 d.p.i. (Fig. 2A). At 14 d.p.i., the amount of
Muc1 mRNA was significantly greater in the lungs of infected mice compared to mock
infected mice. However, the amount of Muc1 protein in whole lung homogenate was not
substantially different between mock infected and infected mice at 14 d.p.i. (Figs. 2C, 2D).
mRNA levels of Muc5ac (Fig. 2B) and gob-5 (data not shown), genes encoding other
mucins, were not substantially upregulated at any time point in mock infected or infected
mice. Likewise, PAS staining revealed no histological evidence of significant mucus
production in the lungs of infected or mock infected mice (Fig. 2E). Thus, despite the
induction of TNF-α production in the lungs, acute MAV-1 respiratory infection was not
associated with substantially increased production of Muc1 protein specifically or lung
mucus production in general.
3.3. MAV-1 Respiratory Infection in Muc1−/− Mice
Although MAV-1 infection did not increase Muc1 production in the lungs, it remained
possible that Muc1 plays a protective role, serving as a physical barrier that limits contact
between MAV-1 and a target cell. We hypothesized that Muc1 deficiency would therefore
facilitate interactions between virus and cell and lead to increased viral loads. To address
this hypothesis, we used qPCR to quantify viral loads in the lungs of Muc1+/+ and Muc1−/−
mice. As previously reported (Anderson et al., 2009; Nguyen et al., 2008; Weinberg et al.,
2007; Weinberg et al., 2005), we used qPCR measurements of MAV-1 DNA as a sensitive
way to quantify viral loads in the lungs of infected mice. As in the experiment described
above, the greatest lung viral loads in Muc1+/+ mice were detected at 4 and 7 d.p.i. (Fig.
3A). Lung viral loads were significantly greater in Muc1−/− mice than in Muc1+/+ mice at 4,
7, and 9 d.p.i., with the largest difference between groups at 9 d.p.i. No differences in lung
viral loads were detected at 14 d.p.i. To provide a separate measure of viral replication, we
used RT-qPCR to quantify the expression of the MAV-1 hexon gene in the lungs at 7 d.p.i.
Hexon expression was significantly greater in the lungs of Muc1−/− mice compared to
Muc1+/+ mice (Fig. 3B), further suggesting that MAV-1 replication was greater in the
absence of Muc1 and that the differences in DNA viral loads were not entirely explained by
differences in clearance of viral DNA from the lungs. In addition, no differences in spleen
viral loads were detected between Muc1+/+ and Muc1−/− mice at any time point (data not
shown).
3.4. MAV-1-Induced Pulmonary Inflammation in Muc1−/− Mice
We anticipated that higher lung viral loads in Muc1−/− mice would be associated with a
greater degree of pulmonary inflammation than in Muc1+/+ mice. Muc1 negatively regulates
TLR-mediated inflammation (Ueno et al., 2008); the absence of such negative regulation
could also lead to increased inflammation in Muc1−/− mice following MAV-1 infection. To
determine whether this was the case, we first evaluated histologic evidence of MAV-1-
induced inflammation in the lungs of Muc1+/+ and Muc1−/− mice at multiple time points
(Fig. 4). Similar to our previous reports (Weinberg et al., 2007; Weinberg et al., 2005),
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patchy areas of cellular inflammation developed in the lungs of Muc1+/+ mice beginning at 7
d.p.i. but were diminished by 14 d.p.i. Areas of cellular infiltration were occasionally more
pronounced in the lungs of Muc1−/− mice than in Muc1+/+ mice at 7 d.p.i. and 14 d.p.i.
(compare Figs. 4A and 4B), but these differences were subtle. Pathology index scores (Table
2) were used to quantify lung inflammation in available lung sections (Fig. 4G). There were
no statistically significant differences between pathology scores in Muc1+/+ and Muc1−/−
mice. Pathology scores were slightly higher in Muc1−/− mice compared to Muc1+/+ mice at
14 d.p.i., but these differences were not statistically significant.
MAV-1 infection induces the expression of multiple cytokines and chemokines in the lungs
(Weinberg et al., 2007; Weinberg et al., 2005). Using RT-qPCR and ELISA, we quantified
lung expression of representative chemokines in order to determine whether their induction
was different in the absence of Muc1. In Muc1+/+ mice, MAV-1-induced lung expression of
CXCL1, CCL5, and CCL2 peaked between 7 and 9 d.p.i. and then decreased by 14 d.p.i.
(Fig. 5). CCL5 mRNA levels were lower in the lungs of Muc1−/− mice than in Muc1+/+
mice at 7 d.p.i. (Fig. 5C), but CCL5 protein levels were comparable between groups at this
time point (Fig. 5D). Otherwise, there were no statistically significant differences in lung
expression of the measured chemokines between Muc1+/+ and Muc1−/− mice at any time
point. Likewise, there were no differences between Muc1+/+ and Muc1−/− mice in lung
expression of the cytokines IFN-γ and TNF-α (data not shown).
4. Discussion
The mucus layer in the airways provides protection against airborne pathogens and other
airborne particles (Hattrup and Gendler, 2008; Knowles and Boucher, 2002; Thornton et al.,
2008). At the same time, increased mucus production during respiratory viral infection can
be deleterious to the host, contributing to the pathophysiology of respiratory infection and
virus-induced exacerbations of chronic lung disease (Footitt and Johnston, 2009). Many
respiratory viruses have been shown to induce lung mucus production in animal models
(Bartlett et al., 2008; Hamelin et al., 2006; Moore et al., 2009), but very little is known about
the ability of an adenovirus to induce mucus production in the lung. Using MAV-1 in its
natural host, we demonstrated that acute respiratory infection with an adenovirus did not
substantially induce lung production of mucus and specifically of Muc1.
Other reports have demonstrated RSV-induced MUC1 upregulation in A549 cells (a human
lung epithelial cell line) and RSV-induced Muc1 upregulation in primary mouse tracheal
surface epithelial cells (Li et al., 2010). We may have missed similar effects of MAV-1 on
Muc1 production in specific cell types by examining whole lung Muc1 mRNA and protein
following in vivo infection. Although unlikely to explain large differences between effects
of MAV-1 on Muc1 mRNA and protein, it is possible that post-translational effects on Muc1
expression, such as the release of Muc1 from the surface of epithelial cells by the action of
cell surface proteases (reviewed in Brayman et al., 2004), could account for some of the
differences we observed between Muc1 mRNA and protein levels. Viral infection likely
affects Muc1/MUC1 expression indirectly via the actions of cytokines produced by infected
cells. For instance, TNF-α induces MUC1 expression in A549 cells and Muc1 expression in
primary mouse tracheal surface epithelial cells (Koga et al., 2007), and RSV induction of
MUC1 production in a human respiratory epithelial cell line is suppressed by TNF-α
inhibition (Li et al., 2010). Other cytokines are also capable of inducing Muc1/MUC1
production. Exposure to IFN-γ, either by itself or in combination with other cytokines such
as IL-1β or TNF-β, increases MUC1 mRNA and protein in a variety of cell lines, including
ovarian carcinoma cells lines (Clark et al., 1994), an oral epithelial cell line (Li et al., 2003),
and several non-small cell lung carcinoma cell lines including A549 cells (Reddy et al.,
2003). While increased IFN-γ levels are present in the lungs of MAV-1-infected mice (Fig.
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5D and Weinberg and Procario, unpublished data), it is possible that differential induction of
other cytokines not measured in our study could account for the different abilities of MAV-1
and RSV to induce Muc1/MUC1 production.
To address the question of whether Muc1 serves a protective function during adenovirus
respiratory infection, we compared the susceptibilities of Muc1+/+ and Muc1−/− mice using
lung viral loads as a surrogate marker for susceptibility. Muc1 deficiency was associated
with an approximately 1-log increase in MAV-1 viral loads in the lungs of Muc1−/− mice
compared to Muc1+/+ mice at several time points. Changes of a similar magnitude have been
described in models using HAdV-based vector gene transfer, with a 2- to 5-fold increased
efficiency of gene transfer following neuraminidase treatment (removing sialic acid residues
from MUC1 and other membrane glycoproteins) of primary human bronchial epithelial cells
in vitro and of human airway xenografts in vivo (Arcasoy et al., 1997). Likewise, the
efficiency of HAdV vector-based gene transfer is increased in Muc1-deficient mice, with
4.9% of tracheal surface area in Muc1−/− mice showing evidence of gene transfer compared
to 1.6% in Muc1+/+ mice (Stonebraker et al., 2004). One likely explanation for the
differences observed in these studies as well as ours is that Muc1/MUC1 normally
contributes to a physical barrier in the lung, preventing virus particles from gaining access to
receptors on target cells in the airways. Muc1 is only one of many components of airway
mucus (Hattrup and Gendler, 2008; Thornton et al., 2008). It seems likely that components
other than Muc1 would still be able to form an effective barrier in Muc1−/− mice to impede
the access of pathogens such as MAV-1 to target cells in the lungs, preventing even larger
differences in lung viral loads than those that we observed in this study.
Muc1/MUC1 has anti-inflammatory properties in addition to its potential role as a physical
barrier. Signaling by multiple TLRs is suppressed by MUC1 (Kim and Lillehoj, 2008; Lu et
al., 2006; Ueno et al., 2008). Exaggerated pulmonary inflammation in Muc1−/− mice
infected with Pseudomonas aeruginosa is associated with more efficient bacterial clearance
from the lungs (Lu et al., 2006). A similar effect may occur during viral infections. For
instance, RSV-induced TNF-α release is enhanced in Muc1−/− primary mouse tracheal
epithelial cells and by MUC1 knockdown in A549 cells, whereas MUC1 overexpression
suppresses TNF-α release induced by RSV infection of A549 cells (Li et al., 2010). We
observed no pronounced differences between Muc1+/+ and Muc1−/− mice in MAV-1-
induced cellular inflammation in the lungs (Fig. 4) and lung chemokine responses (Fig. 5).
Interactions between MAV-1 and specific TLRs or other pattern recognition receptors have
not yet been reported. It is possible that MAV-1 induces inflammatory responses via pattern
recognition receptors or other mechanisms that are not modulated by Muc1 and so do not
differ in the absence of Muc1. It is also possible that Muc1 deficiency led to enhanced
production of inflammatory mediators not measured in our study. However, MAV-1 viral
loads were equivalent in the lungs of Muc1+/+ and Muc1−/− mice by 14 d.p.i. (Fig. 3),
suggesting that any missed effect of Muc1 deficiency on MAV-1-induced inflammation did
not substantially alter the kinetics of virus clearance from the lungs and therefore had little
biological relevance.
In summary, we show that MAV-1 respiratory infection did not affect Muc1 expression in
vivo. Viral loads were greater in Muc1−/− mice than in Muc1+/+ mice, suggesting that Muc1
contributes to a physical barrier that inhibits MAV-1 access to target cells in the airways.
The absence of substantial changes in virus-induced lung inflammation in Muc1−/− mice
compared to Muc1+/+ controls suggests that the anti-inflammatory functions of Muc1 do not
play a prominent role in MAV-1 respiratory infection. Overall, Muc1 is likely to be
protective in the context of acute MAV-1 respiratory infection. However, as with HAdV-
based vectors for gene delivery (Arcasoy et al., 1997; Stonebraker et al., 2004), Muc1 (and
Nguyen et al. Page 8













MUC1 in humans) may impede efforts to use MAV-1 or other non-human adenoviruses as
alternative platforms for gene delivery.
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• We used MAV-1 to determine the role of Muc1 in adenovirus pathogenesis.
• MAV-1 did not increase lung Muc1 production.
• MAV-1 viral loads were higher in the lungs of Muc1-deficient mice.
• Muc1 deficiency did not affect MAV-1-induced lung inflammation.
• Muc1 likely contributes to a physical barrier protecting against MAV-1
infection.
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In vivo induction of TNF-α by MAV-1. Mice were infected intranasally with MAV-1 or
mock infected with conditioned media. (A) RNA was extracted from lungs harvested at the
indicated time points and RT-qPCR was used to quantify the expression of TNF-α. Data for
both experimental groups are presented as expression relative to naïve control mice, whose
value is set at 1 (indicated with horizontal dashed line). Combined data from two
independent experiments (total n=5-14 mice per group) are presented as means ± S.E.M. (B)
ELISA was used to quantify TNF-α protein in lung homogenate obtained from a subset of
mice. Combined data from 5 mice per group are presented as means ± S.E.M. **P<0.01
compared to uninfected mice using two-way ANOVA followed by Bonferroni's multiple
comparison tests at a given time point.
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In vivo induction of Muc1 by MAV-1. Mice were infected intranasally with MAV-1 or
mock infected with conditioned media. RNA was extracted from lungs harvested at the
indicated time points. RT-qPCR was used to quantify the expression of (A) Muc1 and (B)
Muc5ac. Data for both experimental groups are presented as expression relative to naïve
control mice, whose value is set at 1 (indicated with horizontal dashed line). Combined data
from two independent experiments (total n=5-14 mice per group) are presented as means ±
S.E.M. **P<0.01 compared to uninfected mice using two-way ANOVA followed by
Bonferroni's multiple comparison tests at a given time point. (C) Western blot was used to
detect Muc1 protein in whole lung homogenate obtained from representative animals at 14
d.p.i. (D) Quantified Western blot data are presented as the ratio of Muc1 to actin densities
(n=4 to 5 per group, means ± S.E.M). (E) Lung sections were stained with PAS to evaluate
mucus production in the lungs. Scale bars, 100 μm.
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Viral loads in the lungs of Muc1−/− mice. Muc1−/− mice and Muc1+/+ control mice were
infected intranasally with MAV-1. (A) DNA was extracted from lungs harvested at the
indicated time points. qPCR was used to quantify MAV-1 genome copies in lung DNA.
DNA viral load data are expressed as copies of MAV-1 genome per 100 ng of input DNA.
(B) RNA was extracted from lungs of mice at 7 d.p.i. and RT-qPCR was used to quantify
expression of the MAV-1 hexon gene. Data are expressed as copies of hexon per 106 copies
of GAPDH. Combined data from three independent experiments are presented with
individual circles representing values for individual mice and horizontal bars representing
means for each group. *P<0.05, ** P<0.01, and *** P<0.001 comparing two groups at a
given time point using Mann-Whitney rank sum test.
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MAV-1-induced lung inflammation in Muc1−/− mice. Muc1−/− mice and Muc1+/+ control
mice were infected intranasally with MAV-1. Lungs were harvested at 7 d.p.i. (A–D) and 14
d.p.i. (E, F). Hematoxylin and eosin-stained sections were prepared from paraffin-embedded
sections. Regions delineated by the rectangles in A and B are further magnified in C and D.
Scale bars, 100 μm. (G) Pathology index scores were generated to quantify cellular
inflammation in the lungs of Muc1+/+ and Muc1−/− mice. Data are presented as means ±
S.E.M. at each time point (n=2 at 4 and 14 d.p.i., n=4 at 7 and 9 d.p.i.).
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MAV-1-induced chemokine and cytokine expression in Muc1−/− mice. Muc1−/− mice and
Muc1+/+ control mice were infected intranasally with MAV-1. (A, C, E) RNA was extracted
from lungs harvested at the indicated time points. RT-qPCR was used to quantify the
expression of the indicated chemokines. Data for both experimental groups are presented as
expression relative to uninfected control mice, whose value is set at 1 (indicated with
horizontal dashed line). Data (n=5 to 11 mice per group) are presented as means ± S.E.M.
**P<0.01 compared to Muc1+/+ controls at the same time point. (B, D, F) ELISA was used
to quantify the indicated chemokines in whole lung homogenate. Data are presented as
means ± S.E.M. (n=4 to 13 per group).
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Table 1
Primers and probes used for real-time PCR analysis
Target Oligonucleotide Sequence (5′ to 3′)
MAV-1 E1A Forward primer GCACTCCATGGCAGGATTCT
Reverse primer GGTCGAAGCAGACGGTTCTTC
Probe TACTGCCACTTCTGC
MAV-1 Hexon Forward primer GGCCAACACTACCGACACTT
Reverse primer TTTTGTCCTGTGGCATTTGA
Probe CATTCCAGCCAACTTATGGCTCGGC
IFN-γ Forward primer AAAGAGATAATCTGGCTCTGC
Reverse primer GCTCTGAGACAATGAACGCT
TNF-α Forward primer CCACCACGCTCTTCTGTCTAC
Reverse primer AGGGTCTGGGCCATAGAACT
Muc1 Forward primer CACACTCACGGACGCTACGT
Reverse primer TACCTGCCGAAACCTCCTCAT
Muc5ac Forward primer CCAGCACCATCTCTACAACCC
Reverse primer GCAAAGCTCCTGTTTGCACTC
GAPDH Forward primer TGCACCACCAACTGCTTAG
Reverse primer GGATGCAGGGATGATGTTC
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Table 2
Quantification of cellular inflammation in histologic specimens.
Scorea Cellular Infiltrates Around Airway Lumens Pneumonitis
0 No infiltrates No infiltrates
1 1 to 3 cell diameters thick Increased cells visible only at high power
2 4 to 10 cell diameters thick Easily seen cellular infiltrates
3 >10 cell diameters thick Extensive consolidation by inflammatory cells
a
A score from 0 to 3 was given for each of the two categories. The score for each category was multiplied by a number reflecting the extent of
involvement in the specimen (5% to 25% = 1, >25% to 50% = 2, >50% = 3). The final pathology index score was obtained by adding together
values for each category, resulting in a total score that could range from 0 to 18.
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